In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control

Diabetes Care

Volumn 27, Issue 2, 2004, Pages 484-490

  Pistrosch, Frank ^a   Passauer, Jens ^a   Fischer, Sabine ^a   Fuecker, Katja ^a   Hanefeld, Markolf ^b   Gross, Peter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; IBUPROFEN; INSULIN; N(G) METHYLARGININE; NATEGLINIDE; NEUTRAL INSULIN; NITRIC OXIDE SYNTHASE; ROSIGLITAZONE;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; BLOOD FLOW; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFICACY; ENDOTHELIUM INJURY; FEMALE; FOREARM BLOOD FLOW; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; REFERENCE VALUES; THIAZOLIDINEDIONES;

EID: 0842289940     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.2.484     Document Type: Article

References (31)

1. Haffner SM: Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 84:11J-14J, 1999
2. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458, 2000
3. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
4. Behrendt D, Ganz P: Endothelial function: from vascular biology to clinical applications. Am J Cardiol 21:40L-48L, 2002
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A: Long term follow up in patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954, 2000
6. Schachinger V, Britten MB, Zeiher AM: Prognostic value of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906, 2000
7. McVeigh GE, Brennan GM, Johnstone GD: Impaired endothelium dependent and independent vasodilation in patients with type II diabetes mellitus. Diabetologia 35:771-776, 1992
8. Williams SB, Cuso JA, Roddy M, Johnstone MT, Creager MA: Impaired nitric oxide mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27:567-574, 1996
9. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974, 2000
10. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at Akt site. J Clin Invest 108:1341-1348, 2001
11. Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, Kurachi Y: Nateglinide, a D-phenylalanine derivate specifically inhibits pancreatic beta cell type K(ATP) channels. J Pharmacol Exp Ther 304:1025-1032, 2003
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (Suppl. 1):S4-S19, 2002
13. Carlsson I, Vennmalm A: Effect of different prostaglandin synthesis inhibitors on post-occlusive blood flow in human forearm. Prostaglandins 26:241-252, 1983
14. Passauer J, Büssemaker E, Range U, Plug M, Gross P: Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium dependent vasodilation in normotensive subjects on chronic hemodialysis. J Am Soc Nephrol 11:1726-1734, 2002
15. Cardillo C, Nambi SS, Kilcoyne CM, Choucai WK, Katz A, Quon MJ, Panza JA: Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100:820-825, 1999
16. Stroes ESG, Luscher TF, deGroot FG, Koomans HA, Rabelink T: Cyclosporin A increases nitric oxide activity in vivo. Hypertension 29:570-575, 1997
17. Dawes M, Chowienczyk PJ, Ritter JM: Quantitative aspects of the inhibition by N (G)-monomethyl-L-arginine of response to endothelium-dependent vasodilators in human forearm vasculature. Br J Pharmacol 134:939-944, 2001
18. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
19. van Etten RW, de Koning EJP, Verhaar MC, Gaillard CAJM, Rabelink TJ: Impaired NO-dependent vasodilation in patients with type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45:1004-1010, 2002
20. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610, 1996
21. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves M, Schiffrin E: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats. Circulation 105:2296-2302, 2002
22. Walker AB, Chattington PD, Buckingham RE, Williams G: The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1453, 1999
23. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A: The effects of troglitazone on the endothelial function in early and late type 2 diabetes: a placebo controlled randomized clinical trial. Metabolism 52:173-180, 2003
24. Tack CJ, Ong MK, Lutterman JA, Smits P: Insulin induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 41:569-576, 1998
25. Martens FMAC, Visseren FLJ, Lemay J, de Koning EJP, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs 62:1463-1480, 2002
26. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium dependent vasodilation. J Clin Invest 100:1230-1239, 1997
27. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowskt P, Park JY, King GL, Logerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48:1856-1862, 1999
28. Vinik AI, Stansberry KB, Barlow PM: Rosiglitazone treatment increases nitric oxide production in human peripheral skin. J Diabetes Complications 17:279-285, 2003
29. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Gödecke A, Huang PL, Vanhoutte PM, Fleming I, Busse R: An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A 97:9747-9752, 2000
30. Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Kistorp CN, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 50: 2611-2618, 2001
31. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quong MJ: Role for insulin receptor, PI3-kinase, and Akt in insulin-signalling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539-1545, 2000